British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...

British consumer healthcare group Haleon lowered its annual revenue growth forecast to about 3.5% on Thursday after ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

GlaxoSmithKline ( ($GSK) ) has released its Q2 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

A new tuberculosis (TB) vaccine candidate, M72/AS01E, has entered Phase III clinical trials, with Kenyans among the 20,000 ...

If successful, M72 might be the first new TB vaccine in more than a century to meet the WHO's target product profile, ...

Health Sanofi, GlaxoSmithKline set to start Phase 3 trials for COVID-19 vaccine after earlier setback In December, companies said early trials showed 'insufficient' immune response in older adults ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline, with a price target of £14.50. The company’s shares closed yesterday at p1,402.50. Take advantage of ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline today and set a price target of £13.48. The company’s shares closed today at p1,344.00. Take advantage of TipRanks Premium ...

The deal would give GSK the rights to develop the drug for HRD-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...